Last Friday, Pfizer announced that the clinical trial for their COVID-19 antiviral pill, Paxlovid, demonstrated high efficacy in preventing severe COVID-19 in at-risk persons. Paxlovid is unique and differs from Merck’s COVID-19 antiviral, Molnupiravir, by binding to enzymes responsible for the replication of SARS-CoV-2 and inhibiting its life cycle.
Read More »Last Thursday, the UK became the first country to approve an antiviral drug for COVID-19. Molnupiravir, developed by Merck and Ridgeback Biotherapeutics, is designed to stop SARS-CoV-2 from replicating by disrupting its genetic code.
Read More »This morning, the pharmaceutical company Merck submitted an application for EUA of their COVID-19 oral antiviral pill. If accepted, this will become the first pill authorized by the FDA to treat COVID-19. Other FDA authorized COVID-19 treatments must be administered intravenously or via injection.
Read More »AstraZeneca released a press release today stating that their long-acting antibody (LAAB) combination, AZD7442, has been shown to reduce the risk of symptomatic Covid-19 by 77% in a clinical trial. The trial included many participants who had medical conditions placing them at greater risk of severe illness and those who had not been producing sufficient antibodies after vaccination.
Read More »